Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment

Fig. 3

SI-2 treatment alters the tumor-infiltrating immune cell repertoire in E0771 tumors. A Numbers of CD4 + T cells in E0771 tumors in C57BL/6J mice treated with SI-2 (2.5 mg/kg) or vehicle, as determined using IHC with an antibody against CD4. Quantification of the percentage of labeled cells (PLC) with CD4 in E0771 tumors is shown in the graph. B Numbers of CD8 + T cells in E0771 breast tumors treated with SI-2 (2.5 mg/kg) or vehicle, as determined using IHC with an antibody against CD8. Quantification of the PLC for CD8 in E0771 tumors is shown in the graph. C Numbers of CD56 + cells in E0771 tumors treated with SI-2 (2.5 mg/kg) or vehicle, as determined using IHC with an antibody against CD56. The PLC for CD56 is shown in the graph. D Numbers of Ifng-expressing cells in E0771 tumors treated with SI-2 (2.5 mg/kg) or vehicle examined by IHC with Ifng antibody. The PLC for Ifng is shown in the graph. E Numbers of Foxp3 + T cells in E0771 tumors treated with SI-2 (2.5 mg/kg) or vehicle, as determined using IHC with an antibody against Foxp3. The PLC for Foxp3 in E0771 tumors is shown in the graph. F Dual immunofluorescence staining to determine CD4 + (green), Foxp3 + (red), and CD4 + /Foxp3 + or CD4-/Foxp3 + cells in E0771 breast tumors from mice treated with vehicle and SI-2 (2.5 mg/kg) for 35 days. The numbers of CD4 + /Foxp3 + and CD4-/Foxp3 + cells in E0771 breast tumors treated with vehicle and SI-2 (2.5 mg/kg) in Panel F are quantified

Back to article page